1 **VCF2CNA: A tool for efficiently detecting copy-number**
2 **alterations in VCF genotype data**

3

4 Daniel K. Putnam, Xiaotu Ma, Stephen V. Rice, Yu Liu, Jinghui Zhang and Xiang Chen

5 Department of Computational Biology, St. Jude Children's Research Hospital, Memphis

6 TN, USA

7

8 Correspondence: xiang.chen@stjude.org

9 **Abstract**

10 VCF2CNA is a web interface tool for copy-number alteration (CNA) analysis of VCF
 11 and other variant file formats. We applied it to 46 adult glioblastoma and 146 pediatric
 12 neuroblastoma samples sequenced by Illumina and Complete Genomics (CGI) platforms
 13 respectively. VCF2CNA was highly consistent with a state-of-the-art algorithm using
 14 raw sequencing data (mean F1-score=0.994) in high-quality glioblastoma samples and
 15 was robust to uneven coverage introduced by library artifacts. In the neuroblastoma set,
 16 VCF2CNA identified MYCN high-level amplifications in 31 of 32 clinically validated
 17 samples compared to 15 found by CGI's HMM-based CNA model. The findings suggest
 18 that VCF2CNA is an accurate, efficient and platform-independent tool for CNA analyses
 19 without accessing raw sequence data.

20
 21 **Keywords:** VCF2CNA, Copy-number alteration (CNA), Cancer genomics

Background

Copy-number alterations (CNAs) are gains or losses in chromosomal segments that frequently occur in tumor cells. Recent surveys suggest that certain cancers are driven by CNAs [1]. In addition to directly affecting cancer genes (e.g., *MYCN* and *MDM2* amplifications and *RBI* and *CDKN2A* deletions), CNAs mediate oncogene overexpression through enhancer hijacking [2-5]. Several experimental methods are available to identify CNAs in tumor cells. Fluorescence in situ hybridization provides direct evidence of CNAs and is the gold standard for CNA detection in a targeted region [6]. Before the development of next-generation sequencing (NGS) technologies, array comparative genomic hybridization and high-resolution single nucleotide polymorphism (SNP) arrays permitted genome-wide evaluation of CNAs at 30-kb to 100-kb resolution.

The development of NGS, especially whole-genome sequencing (WGS) platforms, has revolutionized the detection of somatic mutations, including CNAs, in cancer samples. For example, Copy Number Segmentation by Regression Tree in Next Generation Sequencing (CONSERTING) [7] incorporates read-depth and structural-variation data from BAM files for accurate CNA detection in high-coverage WGS data. However, CONSERTING and other WGS-based CNA algorithms produce a fractured genome pattern (i.e., a hypersegmented CNA profile with an excessive number of intrachromosomal translocations) in samples with library construction artifacts [7], which poses a major challenge for precise CNA inference. Our extensive analysis indicated that although CNA and structural-variation detection was severely impaired by library artifacts, point-mutation detection was largely unaffected (data not shown), suggesting that a robust CNA tool can be developed from the variant information. Moreover,

CONSORTING and other WGS algorithms require direct access to aligned BAM files. Most algorithms further incur complicated installation steps, which create barriers for their widespread adoption. Advances in technology and declines in costs have made NGS a commodity for both basic research and clinical service. Therefore, a robust CNA analytical tool that is efficient, convenient, and robust to library artifacts is needed to manage the demands of NGS data analysis.

VCF2CNA (<http://vcf2cna.stjude.org>) is a web-based tool for CNA analysis. The preferred input to VCF2CNA is a Variant Call Format (VCF) file. VCF is a widely adopted format for genetic variation data exchange, and VCF files are quite small compared to WGS BAM files. Each variant in a typical VCF file contains its chromosome position, reference/alternative alleles, and corresponding allele counts, which are used by VCF2CNA to identify copy-number alterations. This tool also accepts input in the Mutation Annotation Format (MAF) and the variant file format produced by the Bambino program [8].

Results

VCF2CNA has a simple interface (Fig. 1a). The sole input is a VCF file (or a file in one of the other supported variant file formats) from a paired tumor–normal WGS analysis, which is uploaded via the interface to a web server where the application runs. The results are returned to a user-provided email address. VCF2CNA consists of two main modules: 1) SNP information retrieval and processing from the input data and 2) recursive partitioning–based segmentation using SNP allele counts (Fig. 1b). Actual

running time for a typical sample is approximately 30 to 60 minutes, depending on the complexity of the genome.

To evaluate the utility of VCF2CNA, we ran it on 192 tumor–normal WGS data sets. These sequences comprised 46 adult glioblastomas (GBMs) from The Cancer Genome Atlas (TCGA-GBM) dataset [9], sequenced by Illumina technology, and 146 pediatric neuroblastomas (NBLs) from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET-NBL) dataset (unpublished), sequenced by Complete Genomics, Inc. (CGI) technology. On average, VCF2CNA used approximately 2.8 million high-quality SNPs per sample (median 2,811,245; range, 2,029,467–3,519,454 in TARGET-NBL data) to derive CNA profiles.

CNA analysis of TCGA-GBM data

The adult TCGA-GBM data downloaded from dbGaP (accession number: phs000178.v8.p7) included 46 samples. We first evaluated VCF2CNA’s resistance to library construction artifacts by using 24 samples from this set, which were previously identified as having a fractured genome pattern by CONSERING and other CNA algorithms [7]. Indeed, VCF2CNA produced CNA profiles that are globally consistent with those of SNP array–derived CNA profiles (downloaded from TCGA, Additional file 1.1 and 1.2) and more robust to noise than those produced by CONSERING. Specifically, VCF2CNA yielded a mean 59.4-fold reduction in the number of predicted segments than did CONSERING (median, 46.2; range, 16.2–285.7; $p = 3.0 \times 10^{-6}$ by Wilcoxon signed-rank test, Fig. 2a and Additional file 1).

We used an F_1 scoring metric [10] to measure the consistency between the CNA profiles derived from VCF2CNA and CONSERING in the remaining 22 high-quality

sample pairs (Fig. 2b and Additional file 2). These programs identified approximately 700 Mb of the CNA regions in each sample (range, 92–2299 Mb) with high consistency (mean F_1 score, 0.9941; range, 0.9699–0.9995) (Table 1).

We evaluated the segmental overlap between the CONsertING outputs and the VCF2CNA outputs for each sample. A CNA segment detected by CONsertING was classified as corroborated if 90% of the bases in the segment received the same type of CNA call from VCF2CNA (Table 2). The comparison shows that VCF2CNA faithfully recapitulated medium to large CNA segments (≥ 100 kb) (Fig. 3a), whereas CONsertING had greater power for identifying focal (< 100 kb) low-amplitude (absolute $\log_2$ ratio change < 1.0) CNAs ($p = 1.306 \times 10^{-5}$ by Wilcoxon signed-rank test, Fig. 3b). Furthermore, the segmental-based analysis revealed that the detection power was less affected in focal CNAs with large amplitudes ($\log_2$ ratio ≥ 3.0) (Fig. 3c).

To further test whether VCF2CNA accurately captures the CNA patterns in samples with library artifacts, we applied the cghMCR algorithm [11]. This algorithm identifies genomic regions that exhibit common gains and losses across all 46 samples from either VCF2CNA profiles or SNP array-derived CNA profiles (downloaded from TCGA). Although the signal from VCF2CNA contained less noise than did the signal from the SNP array in most samples (Additional file 1), both profiles reveal common recurrently amplified and/or lost regions (Fig. 4). These changes included chromosome-level changes (i.e., chr7 amplifications and loss of chr10) and segmental CNAs (i.e., focal deletion of the *CDKN2A/B* locus on chr9p) [12]. Moreover, VCF2CNA identified recurrent losses in *ERBB4* on chr2q and *GRIK2* on chr6q that were absent in the SNP array profiles. *ERBB4*

encodes a transmembrane receptor kinase that is essential for neuronal development [13]. It is frequently mutated in patients with non-small cell lung cancer [14], and silencing of *ERBB4* through DNA hypermethylation is associated with poor prognosis in primary breast tumors [15]. Similarly, *GRIK2* is a candidate tumor suppressor gene that is frequently deleted in acute lymphocytic leukemia [16] and silenced by DNA hypermethylation in gastric cancer [17].

Amplifications such as double minute chromosomes and homogeneously staining regions represent a common mechanism of oncogene overexpression in tumors [18]. Among the 46 TCGA-GBM samples analyzed, VCF2CNA identified double minute chromosomes in 34 samples affecting the *EGFR* [19], *MDM2* [20], *MDM4* [21], *PDGFRA* [22], *HGF* [23], *GLI1* [24], *CDK4* [25], and *CDK6* [26] genes (Fig. 5 and Additional file 3). These events consisted of high-level amplifications in 21 samples with potential fractured genome patterns (Additional file 3a) and 13 previously reported samples (Additional file 3b) [7, 27].

CNA analysis of TARGET-NBL data

We applied VCF2CNA to the TARGET-NBL dataset downloaded from dbGap (assessment number: phs000467). This dataset consists of 146 tumors with matched normal WGS samples, sequenced with CGI technology. Because the ligation-based CGI technology has notable differences in the detection of single nucleotide variants (SNVs) and insertions/deletions (indels) compared to Illumina systems [28], this dataset provided an opportunity to evaluate VCF2CNA's robustness using different sequencing platforms.

We used VCF2CNA to perform cghMCR analysis with CNA profiles and observed a genome pattern similar to that reported for SNP array platforms (Fig. 6a) [29]. In addition

to loss of large regions on chr1p, 3p, and 11q and a broad gain of chr17q, VCF2CNA found frequent focal amplifications of *MYCN* in NBL tumors and several potential cancer-related CNAs, including high-level amplifications of *CDK4* (1 tumor), and *ALK* (2 tumors) (Fig. 6b).

High-level amplification of *MYCN* is a known oncogenic driver found in ~25% of pediatric patients with NBL, and is associated with aggressive tumors and poor prognosis [30]. A subset of 32 tumors in the TARGET-NBL cohort contains clinically validated amplifications of *MYCN*. Although the CGI's hidden Markov CNA model (unpublished) reported *MYCN* amplifications in 15 of these 32 tumors, VCF2CNA successfully identified high-level amplifications in 31 tumors. In the clinically validated *MYCN*-amplified sample that went undetected by VCF2CNA, a follow-up review revealed that tumor heterogeneity and sampling bias most likely contributed to the discrepancy. Moreover, VCF2CNA predicted two additional *MYCN* amplification events among the remaining tumor samples, indicating that VCF2CNA can identify clinically relevant CNAs that were undetected by traditional methods of CNA detection. The high-level concordance with clinically validated data provides a strong indication that VCF2CNA is applicable to multiple tumor types collected from different sequencing platforms.

Discussion and conclusions

We developed VCF2CNA for the systematic and robust detection of CNAs from VCF and other genotyping variant call formats. Analysis of 192 paired tumor–normal WGS samples sequenced on multiple platforms demonstrates that VCF2CNA is robust to library construction artifacts and captures medium to large CNA segments with high

accuracy. Because VCF2CNA is robust to library artifacts and is highly accurate, it identified recurrent losses in potential tumor suppressors that were undetectable by alternative approaches.

VCF2CNA was designed with SNPs that were (on average) thousands of base pairs apart, which limits support for identifying focal copy-number changes. Therefore, state-of-the-art CNA algorithms have superior detection power for focal low-amplitude CNAs in high-quality, high-coverage WGS data.

In conclusion, VCF2CNA is a web-based tool that is capable of accurate and efficient detection of CNAs from variants called from high-coverage WGS data sequenced on various platforms.

Methods

Server availability

VCF2CNA is available at <https://vcf2cna.stjude.org>.

Parameter definitions

The Specify Diploid Chromosome parameter normalizes results by the specified chromosome. The Median Normal Coverage parameter permits input of the median coverage value of SNPs from normal samples. The Minimum Scale Factor (autosomes) parameter is multiplied by the median to compute the minimum coverage value. The Maximum Scale Factor (autosomes) parameter is multiplied by the median to compute the maximum coverage value. The Minimum X Scale Factor is the minimum scale factor for chromosome X. The Maximum X Scale Factor is the maximum scale factor for chromosome X. The Sample Order (VCF format only) parameter defines the ordering of

tumor and normal samples. VCF inputs must include tumor and normal data after the FORMAT field. Selecting the Tumor/Normal button assigns the tumor data to the first field after FORMAT and normal data to the second field. The Normal/Tumor radio button specifies the reverse order.

Input data for VCF2CNA

The input for VCF2CNA analysis includes VCF, MAF, and the variant file format produced by the Bambino program. A fixed window size of 100 bp is used to obtain the mean coverage for each window. Windows with no variants are ignored. The mean read depth per window can be normalized to a set of reference diploid chromosomal regions by using the same criteria as CONSERING or specified via the Specify Diploid Chromosome parameter.

Run-time analysis

Single VCF files must be converted to a paired tumor/normal file before uploading. Alternatively, VCF2CNA accepts MAF and Bambino variant file formats. After uploading files to the server, the median running time was 23 minutes on an intel Xeon E5-2680 processor at 2.70 Ghz with 64 GB RAM. Server processing occurs in two principal steps: 1) preprocessing and SNP information extraction from input files and 2) running the recursive partitioning segmentation.

F₁ scoring metric and segmental corroboration

A genomic position was assigned a corroborated CNA call if its computed CNA type (gain or loss) by VCF2CNA matched the call computed by CONSERING. A CNA

segment in the CONserting profile was corroborated in the VCF2CNA profile if $\geq 90\%$ of the segment positions were corroborated. The F_1 score is given by $F_1 = \frac{2(\text{precision})(\text{recall})}{\text{precision} + \text{recall}}$. It was used to summarize the accuracy of VCF2CNA, compared with that of CONserting.

VCF2CNA web server pipeline

Step1 (snvcounts)

Single nucleotide variant frequencies are computed from the input file. For each chromosome and position, the values computed are TumorMutant, TumorTotal, NormalMutant, and NormalTotal. Additionally, the mean normal coverage is computed.

Step2 (consprep)

The consprep program reads the SNV count data and incorporates a list of good / bad SNVs. It also reads a file specifying the number of 100-bp windows in each chromosome. If the total number of reads from the normal sample falls outside of the ranges specified by the options (median, minfactor, maxfactor, xminfactor, or xmaxfactor), the input position is ignored by the consprep step in the pipeline. The $-xminfactor$ and $-xmaxfactor$ settings apply to positions in chrX; the $-minfactor$ and $-maxfactor$ settings apply to all other chromosomes. The minimum coverage is the median multiplied by the $-minfactor$, and the maximum coverage is the median multiplied by the $-maxfactor$.

Application

To run VCF2CNA, users should navigate to the application home page and click “run application.” The application runs on Google Chrome, Safari, Mozilla Firefox, and

Microsoft Internet Explorer 11. Users must provide a valid email in the email address text field. Users will select whether results will be sent to the provided email address as either an email attachment or a link to the result files stored on the server. Results will be stored on the server for 14 days. Default run parameters may be modified depending on job specifications. Users should select the input file and click the “upload/run” button. The browser window should not be killed during the file upload. Once the file has been successfully uploaded, a notification will be displayed in the browser window and the user may discard the window.

Rationale for not using the reciprocal-overlap rule

To compare CNA calls from different algorithms, the reciprocal 50% overlap criterion [28] is commonly used. This rule is not suitable when two CNA calls are derived from platforms with different powers in detecting focal CNAs. A considerably larger average distance occurred between adjacent probes. VCF2CNA-derived CNA calls have an inherently lower resolution than does CONSERING. When a focal CNA identified through CONSERING occurs on top of a large CNA fragment, CONSERING breaks the region into multiple segments. Although the CNA fragments in the region are largely corroborated between the two CNA callers, potentially none of these fragments satisfied the rule of reciprocal 50% overlap (Additional file 4).

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Both datasets were downloaded from dbGaP (<https://dbgap.ncbi.nlm.nih.gov>). The TCGA-GBM data were downloaded from dbGaP (accession number: phs000178.v8.p7) and included 46 samples. The TARGET-NBL data were downloaded from dbGap (accession number: phs000467) and included 146 samples. VCF2CNA is available at <https://vcf2cna.stjude.org>.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported by ALSAC.

Authors' contributions

JZ and XC conceived the concept. DP, XM, and XC designed the VCF2CNA algorithm. DP, XM, SR, and XC implemented the algorithm. DP, XM, YL, and XC performed the analysis. DP and XC wrote the manuscript.

Acknowledgements

We thank Dr. Nisha Badders for editing the manuscript and Soubhadra Datta for server support.

References

1. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C: **Emerging landscape of oncogenic signatures across human cancers.** *Nat Genet* 2013, **45**:1127-1133.
2. Groschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BA, Erpelinck C, van der Velden VH, Havermans M, Avellino R, van Lom K, et al: **A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.** *Cell* 2014, **157**:369-381.
3. Hnisz D, Weintraub AS, Day DS, Valton AL, Bak RO, Li CH, Goldmann J, Lajoie BR, Fan ZP, Sigova AA, et al: **Activation of proto-oncogenes by disruption of chromosome neighborhoods.** *Science* 2016, **351**:1454-1458.
4. Northcott PA, Lee C, Zichner T, Stutz AM, Erkek S, Kawauchi D, Shih DJ, Hovestadt V, Zapatka M, Sturm D, et al: **Enhancer hijacking activates GF11 family oncogenes in medulloblastoma.** *Nature* 2014, **511**:428-434.
5. Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, Kramer A, Roncaioli JL, Sand F, Heuckmann JM, et al: **Telomerase activation by genomic rearrangements in high-risk neuroblastoma.** *Nature* 2015, **526**:700-704.
6. Hu L, Ru K, Zhang L, Huang Y, Zhu X, Liu H, Zetterberg A, Cheng T, Miao W: **Fluorescence in situ hybridization (FISH): an increasingly demanded tool for biomarker research and personalized medicine.** *Biomark Res* 2014, **2**:3.
7. Chen X, Gupta P, Wang J, Nakitandwe J, Roberts K, Dalton JD, Parker M, Patel S, Holmfeldt L, Payne D, et al: **CONSERING: integrating copy-number analysis with structural-variation detection.** *Nat Methods* 2015, **12**:527-530.
8. Edmonson MN, Zhang J, Yan C, Finney RP, Meerzaman DM, Buetow KH: **Bambino: a variant detector and alignment viewer for next-generation sequencing data in the SAM/BAM format.** *Bioinformatics* 2011, **27**:865-866.
9. Brennan CW, Verhaak RG, McKenna A, Campos B, Nousemeh H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al: **The somatic genomic landscape of glioblastoma.** *Cell* 2013, **155**:462-477.
10. Van Rijsbergen C: **Foundation of Evaluation.** *Journal of Documentation* 1974, **30**:365-373.
11. Aguirre AJ, Brennan C, Bailey G, Sinha R, Feng B, Leo C, Zhang Y, Zhang J, Gans JD, Bardeesy N, et al: **High-resolution characterization of the pancreatic adenocarcinoma genome.** *Proc Natl Acad Sci U S A* 2004, **101**:9067-9072.
12. Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, Forsyth P, Passe S, Jenkins RB, Aldape KD: **Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma.** *Cancer Res* 2002, **62**:6205-6210.
13. Anton ES, Ghashghaei HT, Weber JL, McCann C, Fischer TM, Cheung ID, Gassmann M, Messing A, Klein R, Schwab MH, et al: **Receptor tyrosine kinase ErbB4 modulates neuroblast migration and placement in the adult forebrain.** *Nat Neurosci* 2004, **7**:1319-1328.
14. Kurppa KJ, Denessiouk K, Johnson MS, Elenius K: **Activating ERBB4 mutations in non-small cell lung cancer.** *Oncogene* 2016, **35**:1283-1291.
15. Das PM, Thor AD, Edgerton SM, Barry SK, Chen DF, Jones FE: **Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells.** *Oncogene* 2010, **29**:5214-5219.

- 320 16. Sinclair PB, Sorour A, Martineau M, Harrison CJ, Mitchell WA, O'Neill E, Foroni L: **A**
321 **fluorescence in situ hybridization map of 6q deletions in acute lymphocytic leukemia:**
322 **identification and analysis of a candidate tumor suppressor gene.** *Cancer Res* 2004,
323 **64**:4089-4098.
- 324 17. Wu CS, Lu YJ, Li HP, Hsueh C, Lu CY, Leu YW, Liu HP, Lin KH, Hui-Ming Huang T, Chang YS:
325 **Glutamate receptor, ionotropic, kainate 2 silencing by DNA hypermethylation**
326 **possesses tumor suppressor function in gastric cancer.** *Int J Cancer* 2010, **126**:2542-
327 2552.
- 328 18. Albertson DG: **Gene amplification in cancer.** *Trends Genet* 2006, **22**:447-455.
- 329 19. Huang PH, Xu AM, White FM: **Oncogenic EGFR signaling networks in glioma.** *Sci Signal*
330 2009, **2**:re6.
- 331 20. Biernat W, Kleihues P, Yonekawa Y, Ohgaki H: **Amplification and overexpression of**
332 **MDM2 in primary (de novo) glioblastomas.** *J Neuropathol Exp Neurol* 1997, **56**:180-185.
- 333 21. Riemenschneider MJ, Buschges R, Wolter M, Reifenberger J, Bostrom J, Kraus JA,
334 Schlegel U, Reifenberger G: **Amplification and overexpression of the MDM4 (MDMX)**
335 **gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2**
336 **amplification.** *Cancer Res* 1999, **59**:6091-6096.
- 337 22. Phillips JJ, Aranda D, Ellison DW, Judkins AR, Croul SE, Brat DJ, Ligon KL, Horbinski C,
338 Venneti S, Zadeh G, et al: **PDGFRA amplification is common in pediatric and adult high-**
339 **grade astrocytomas and identifies a poor prognostic group in IDH1 mutant**
340 **glioblastoma.** *Brain Pathol* 2013, **23**:565-573.
- 341 23. Zhao Y, Sun Y, Zhang H, Liu X, Du W, Li Y, Zhang J, Chen L, Jiang C: **HGF/MET signaling**
342 **promotes glioma growth via up-regulation of Cox-2 expression and PGE2 production.**
343 *Int J Clin Exp Pathol* 2015, **8**:3719-3726.
- 344 24. Kanu OO, Hughes B, Di C, Lin N, Fu J, Bigner DD, Yan H, Adamson C: **Glioblastoma**
345 **Multiforme Oncogenomics and Signaling Pathways.** *Clin Med Oncol* 2009, **3**:39-52.
- 346 25. Reifenberger G, Ichimura K, Reifenberger J, Elkahoul AG, Meltzer PS, Collins VP:
347 **Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests**
348 **CDK4/SAS and MDM2 as independent amplification targets.** *Cancer Res* 1996, **56**:5141-
349 5145.
- 350 26. Costello JF, Plass C, Arap W, Chapman VM, Held WA, Berger MS, Su Huang HJ, Cavenee
351 WK: **Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using**
352 **two-dimensional separation of genomic DNA.** *Cancer Res* 1997, **57**:1250-1254.
- 353 27. Sanborn JZ, Salama SR, Grifford M, Brennan CW, Mikkelsen T, Jhanwar S, Katzman S,
354 Chin L, Haussler D: **Double minute chromosomes in glioblastoma multiforme are**
355 **revealed by precise reconstruction of oncogenic amplicons.** *Cancer Res* 2013, **73**:6036-
356 6045.
- 357 28. Mills RE, Walter K, Stewart C, Handsaker RE, Chen K, Alkan C, Abyzov A, Yoon SC, Ye K,
358 Cheetham RK, et al: **Mapping copy number variation by population-scale genome**
359 **sequencing.** *Nature* 2011, **470**:59-65.
- 360 29. George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, Fox EA, Meyerson M, Diller L,
361 Fortina P, et al: **Genome-wide analysis of neuroblastomas using high-density single**
362 **nucleotide polymorphism arrays.** *PLoS One* 2007, **2**:e255.
- 363 30. Huang M, Weiss WA: **Neuroblastoma and MYCN.** *Cold Spring Harb Perspect Med* 2013,
364 **3**:a014415.

367 **Table 1** F_1 score between CONSERGING and VCF2CNA and autosomal CNAs per
368 sample in 22 TCGA samples

Sample	F_1 score	Autosomal CNAs per sample (Mb)
SJHGG011906_D1_G1_N13	0.9699	567.70
SJHGG010485_D1_G1	0.9840	789.90
SJHGG011903_D1_G1	0.9862	459.20
SJHGG010643_D1_G1_N5	0.9870	1471.67
SJHGG010641_D1_G1	0.9884	285.89
SJHGG010600_R1_G1	0.9892	485.85
SJHGG010484_R1_G1_N2	0.9949	2299.48
SJHGG010560_R1_G1	0.9955	756.08
SJHGG010624_R1_G1	0.9956	1259.68
SJHGG010600_D1_G1	0.9968	389.60
SJHGG010485_R1_G1	0.9970	92.16
SJHGG011904_D1_G1	0.9979	696.48
SJHGG010540_D2_G1	0.9981	660.74
SJHGG010484_D1_G1	0.9983	841.72
SJHGG010509_D1_G1	0.9983	586.18
SJHGG010560_D1_G1	0.9984	551.73
SJHGG010577_D1_G1	0.9984	831.67
SJHGG010509_R1_G1	0.9988	562.44
SJHGG010572_R1_G1	0.9992	427.91
SJHGG010572_D1_G1	0.9994	456.27
SJHGG010624_D1_G1	0.9995	454.09
SJHGG010540_R1_G1	0.9995	463.89

369

370 **Table 2** Counts of corroborated and uncorroborated segments by segment length

Sample	Matched segment length ($\log_{10}$)					Unmatched segment length ($\log_{10}$)					Match percentage	
	<3	[3,4)	[4,5)	[5,6)	>6	<3	[3,4)	[4,5)	[5,6)	>6	<100 kb	≥ 100 kb
SJHGG010484_D1_G1	0	4	45	24	54	2	9	31	3	0	0.5385	0.9630
SJHGG010484_R1_G1_N2	4	8	23	21	90	8	7	3	1	0	0.6604	0.9911
SJHGG010485_D1_G1	8	5	20	20	40	20	25	16	4	1	0.3511	0.9231
SJHGG010485_R1_G1	0	0	0	0	2	9	1	3	1	0	0.0000	0.6667
SJHGG010509_D1_G1	3	0	9	15	24	3	0	5	0	0	0.6000	1.0000
SJHGG010509_R1_G1	5	0	11	11	24	8	1	4	1	0	0.5517	0.9722
SJHGG010540_D2_G1	5	11	46	25	28	4	10	5	0	0	0.7654	1.0000
SJHGG010540_R1_G1	4	9	31	32	22	3	11	9	0	0	0.6567	1.0000
SJHGG010560_D1_G1	9	30	59	32	20	24	39	20	0	0	0.5414	1.0000
SJHGG010560_R1_G1	2	0	5	17	26	24	25	15	3	1	0.0986	0.9149
SJHGG010572_D1_G1	2	5	23	27	26	38	12	7	0	0	0.3448	1.0000
SJHGG010572_R1_G1	2	2	4	24	18	30	18	8	1	0	0.1250	0.9767
SJHGG010577_D1_G1	7	4	24	36	37	15	12	9	2	0	0.4930	0.9733
SJHGG010600_D1_G1	29	26	45	79	32	40	26	17	1	0	0.5464	0.9911
SJHGG010600_R1_G1	18	26	50	65	27	51	28	11	2	0	0.5109	0.9787
SJHGG010624_D1_G1	13	13	114	53	82	32	7	2	0	0	0.7735	1.0000
SJHGG010624_R1_G1	9	8	143	110	202	22	4	17	1	0	0.7882	0.9968
SJHGG010641_D1_G1	27	50	99	62	39	19	325	175	3	0	0.2532	0.9712
SJHGG010643_D1_G1_N5	5	13	22	33	30	24	24	11	15	2	0.4040	0.7875
SJHGG011903_D1_G1	1	0	4	39	13	2	5	0	0	1	0.4167	0.9811
SJHGG011904_D1_G1	1	2	4	14	23	1	1	5	1	0	0.5000	0.9737
SJHGG011906_D1_G1_N13	3	14	42	26	44	10	19	27	3	0	0.5130	0.9589
SJHGG010484_D1_G1	0	4	45	24	54	2	9	31	3	0	0.5385	0.9630

371

Figure legends

Fig. 1 Overview of the VCF2CNA process. **a** User interface with parameters. **b** Server side pipeline. A parallelogram depicts input or output files, a rectangle depicts an analytical process, and a diamond depicts the condition for a follow-up process.

Fig. 2 A Circos plot that displays CNAs found by CONCERTING (outer ring), VCF2CNA (middle ring), and SNP array (inner ring) for **a** TCGA-GBM fractured sample 41-5651-01A and **b** TCGA-GBM unfractured sample 06-0125-01A. Alternating gray and black chromosomes are used for contrast. Yellow regions depict sequencing gaps, whereas red regions depict centromere location. Blue segments depict copy-number loss, and red segments indicate copy-number gain.

Fig. 3 Heatmap of segment length by CNA intensity. Color scale depicts density of segment found at a given segment and CNA size. **a** Corroborated samples, **b** uncorroborated samples, and **c** three-dimensional plots of segment length, CNA intensity, and percent agreement with CONCERTING segments are shown.

Fig. 4 A chgMCR plot of 46 TCGA-GBM samples. **a** SNP array data and **b** VCF2CNA data are shown.

Fig. 5 A Circos plot of VCF2CNA (outer ring) and CONCERTING (inner ring), depicting high-amplitude focal CNA segments in TCGA-GBM sample 06-0152-01A. Included in these segments are the known cancer genes *EGFR*, *CDK4*, and *MDM2*.

Fig. 6 Analysis of the TARGET-NBL dataset, consisting of 146 tumors. **a** A chgMCR plot in which green depicts regions of copy-number gain and red depicts regions of copy-

number loss. **b** A Circos plot showing a focal gain on chromosome 2 for *MYCN* and *ALK5* for sample PARETE-01A-01D.

Additional files

Additional file 1: Circos plot of CONSERING (outer ring), VCF2CNA (middle ring), and SNP array (inner ring) for 24 TCGA-GBM samples with a fractured gene signature.

Additional file 2: Circos plot of CONSERING (outer ring) and VCF2CNA (inner ring) for all 22 TCGA-GBM samples without a fractured gene signature.

Additional file 3: A Circos plot of VCF2CNA (outer ring) and CONSERING (inner ring), depicting high-amplitude focal CNA segments in 34 TCGA-GBM samples. **a** 21 fractured genome TCGA-GBM samples. **b** 13 previously reported samples.

Additional file 4: Segmental Overlap. **a** A hypothetical large segment identified by CONSERING (red). **b** Subsequent focal segments identified by CONSERING (blue). The original segment was split into five subsegments. None of the subsegments in **b** met the reciprocal 50% segment overlap criteria with the original segment.

A

VCF2CNA APP

Select Delivery Method

☒ Attachment
 ☐ Link

Modify Default Parameters ▾

Specify Diploid Chromosome	NA
Median Normal Coverage	NA
Minimum Scale Factor	0.50
Maximum Scale Factor	1.50
Minimum X Scale Factor	0.25
Maximum X Scale Factor	1.50

Sample Order [VCF Format Only]

☒ Tumor/Normal
 ☐ Normal/Tumor

B

A

B

A

B